ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

"Our presentations at this Conference reflect key areas of focus with our research team,” commented Daniel Junius, President and Chief Executive Officer. “We’ll be reporting updated clinical data with our IMGN901 compound when used for the treatment of CD56-expressing solid tumors. This trial has now entered its expansion phase and the findings reported will include the maximum tolerated dose established. Additionally, ImmunoGen scientists will be reporting data related to how compounds made with our engineered linkers and maytansinoid cell-killing agents become activated once inside the targeted cancer cells – findings that help inform our product and our technology research programs. Our scientists also will report data for a new family of cell-killing agents that we’re developing that potentially further expands our product and business development opportunities.”

ImmunoGen posters on Nov. 16, 12:30 – 2:30 PM

• “The effect of linker on target cell catabolism and PK/PD of trastuzumab-maytansinoid conjugates” (abstract #A149) at Poster session A; Drug Metabolism, Transport, and Biodistribution.

ImmunoGen posters on Nov. 17, 12:30 – 2:30 PM

• “Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC)” (abstract #B237) at Poster session B; Therapeutic Agents: Biological 1.
• “Potent antigen-specific anti-tumor activity observed with antibody-drug conjugates (ADCs) made using a new class of DNA-crosslinking agents” (abstract #B126) at Poster session B; Monoclonal Antibodies.
• “Designing potent antibody-drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity” (abstract #B120) at Poster session B; Monoclonal Antibodies.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com